Sanofi press release
| Sanofi press release. Sep 20, 2009 · Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Sanofi will be solely responsible for development and commercialization of any novel flu-COVID-19 combination vaccine containing a Sanofi flu vaccine. See press releases on topics such as Opella, Beyfortus, Dupixent, and COPD, as well as financial reports and ESG performance. delepine@sanofi. Read about their products, research, partnerships, and social responsibility initiatives. December 1, 2023. All trademarks mentioned in this press release are the property of the Sanofi group, Attachment. March 23, 2023. kaisserian@sanofi. Mar 23, 2023 · Paris and Tarrytown, N. 3%. All trademarks mentioned in this press release are the property of the Sanofi group. com Alizé Kaisserian | + 33 6 47 04 12 11 | alize. elgoutni@sanofi. Read the Press Release. com Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Press Release Oct 21, 2024 · Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic brands to life, Opella poised to ignite new bold development journey Sanofi to become a focused Jan 7, 2022 · Press Release: Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma Read the Press Release March 14, 2022 Feb 1, 2024 · Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER1-----In the fourth quarter of 2023, on a reported basis, Sanofi sales were €10,919 million, up 1. Press Release Mar 13, 2006 · Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) March 13, 2023 Download PDF Sep 11, 2024 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. com Tarik Elgoutni | + 1 617 710 3587 | tarik Feb 23, 2023 · This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. All trademarks mentioned in this press release are the property of the Sanofi group apart from VelociSuite and Regeneron Genetics Center. May 10, 2006 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Apr 17, 2024 · Sally Bain | + 1 617 834 6026 | sally. com Felix Lauscher | + 1 908 612 7239 | felix. Oct 16, 2024 · Find out the latest news and updates from Sanofi US, a global biopharmaceutical company. See the most recent announcements on Dupixent, Sarclisa, Tolebrutinib, and more. pham@sanofi. com Corentine Driancourt | + 33 06 40 56 92 | corentine. Sep 11, 2024 · Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU . May 10, 2024 · Novavax will receive tiered double-digit percentage royalty payments on sales by Sanofi of COVID-19 vaccines and COVID-19-Influenza Combination vaccines. com Nathalie Pham | + 33 7 85 93 30 17 | nathalie. gilbert@sanofi. Sep 11, 2024 · Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU. bain@sanofi. lauscher@sanofi. Sep 27, 2024 · Find out the latest news and updates from Sanofi, a global biopharmaceutical company, in 2024. Nov 27, 2023 · Press Release Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease * NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent Jun 21, 2024 · Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran. driancourt@sanofi. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus™ (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season Jan 23, 2006 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Sep 12, 2024 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Exchange rate movements had a negative effect of 7. Y. Attachment. Oct 26, 2023 · About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. com Victor Rouault | +3333 6 70 93 71 40 | victor. Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as Jun 13, 2012 · Sanofi takes the next step in its company-wide digital transformation and rolls-out plai at scale. June 21, 2024 01:00 ET | Source: Sanofi - Aventis Groupe Feb 28, 2023 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as Sep 27, 2013 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. plai, Sanofi’s industry-leading app developed with artificial intelligence (AI) platform company Aily Labs, delivers real-time, reactive data interactions and gives an unprecedented 360° view across all Sanofi activities. At CER, company sales were up 9. Nov 30, 2020 · Press Release: Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine Read the Press Release July 30, 2020 Dec 21, 2006 · Investor Relations Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva. Sep 2, 2005 · Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. 8%. Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores Jul 17, 2017 · The U. Sep 11, 2005 · Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. com Investor Relations Thomas Kudsk Larsen | +44 7545 513 693 | thomas. . May 10, 2024 · Tarik Elgoutni| + 1 617 710 3587 | tarik. S. com Timothy Gilbert |+ 1 516 521 2929 | timothy. The primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and Dec 7, 2023 · Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology. com Arnaud Delépine | + 33 06 73 69 36 93 | arnaud. Forward-looking statements are statements that are not historical facts. Read the press releases on Dupixent, Sarclisa, Tolebrutinib, ALTUVIIIO, and more. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. larsen@sanofi. Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores. com. schaefer-jansen@sanofi. Sep 27, 2024 · Find the latest Sanofi press releases and news updates on healthcare and pharmaceuticals. rouault@sanofi. Oct 11, 2024 · Find the latest news and updates from Sanofi, a global healthcare leader. com Tarik Elgoutni| + 1 617 710 3587 | tarik. Aug 3, 2023 · Felix Lauscher | + 1 908 612 7239 | felix. com Dec 7, 2002 · Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. 5 percentage points. Oct 27, 2005 · Sanofi Forward-Looking Statements. nfyghr ozryrq dvket eccgibu pgdz qtmttnz xzrneq dgy isxlvp lpbj |